BR112015025206A2 - compostos alterando telômero mediados por telomerase - Google Patents
compostos alterando telômero mediados por telomeraseInfo
- Publication number
- BR112015025206A2 BR112015025206A2 BR112015025206A BR112015025206A BR112015025206A2 BR 112015025206 A2 BR112015025206 A2 BR 112015025206A2 BR 112015025206 A BR112015025206 A BR 112015025206A BR 112015025206 A BR112015025206 A BR 112015025206A BR 112015025206 A2 BR112015025206 A2 BR 112015025206A2
- Authority
- BR
- Brazil
- Prior art keywords
- telomerase
- telomer
- mediated
- altering compounds
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo patente de invenção: "compostos alterando telômero mediados por telomerase". a presente descrição refere-se a composições farmacêuticas e métodos de usar 6-mercaptopurina ribosídeos e análogos dos mesmos para o tratamento de câncer e outras doenças hiperproliferativas. os compostos descritos podem ser convertidos em substratos de telômero in vivo e podem ser reconhecidos por telomerase para incorporação em telômeros de células ativas de telomerase, levando à indução de morte da célula das células ativas de telomerase. 1/1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361809575P | 2013-04-08 | 2013-04-08 | |
PCT/US2014/033330 WO2014168947A2 (en) | 2013-04-08 | 2014-04-08 | Telomerase mediated telomere altering compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015025206A2 true BR112015025206A2 (pt) | 2017-07-18 |
Family
ID=50819958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015025206A BR112015025206A2 (pt) | 2013-04-08 | 2014-04-08 | compostos alterando telômero mediados por telomerase |
Country Status (14)
Country | Link |
---|---|
US (1) | US10463685B2 (pt) |
EP (2) | EP3682888A1 (pt) |
JP (1) | JP6525956B2 (pt) |
KR (1) | KR20150143587A (pt) |
CN (2) | CN105338987A (pt) |
AU (1) | AU2014251093B2 (pt) |
BR (1) | BR112015025206A2 (pt) |
CA (1) | CA2907924C (pt) |
HK (1) | HK1219418A1 (pt) |
MX (1) | MX2015014159A (pt) |
NZ (1) | NZ713498A (pt) |
RU (1) | RU2713555C2 (pt) |
SG (2) | SG11201508336TA (pt) |
WO (1) | WO2014168947A2 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180036331A1 (en) * | 2016-03-24 | 2018-02-08 | The Board Of Regents Of The University Of Texas System | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds |
EP3463370A4 (en) * | 2016-05-27 | 2020-04-08 | The Board of Regents of The University of Texas System | 6-THIO-2'-DESOXYGUANOSINE (6-THIO-DG) CAUSES TELOMERASE DEPENDENT TELEOMERS AND CELL DEATH IN THERAPY RESISTANT CANCER CELLS |
AU2019208197A1 (en) | 2018-07-31 | 2020-02-20 | Howmedica Osteonics Corp. | Fixation devices and prostheses for soft tissue connection to the same |
AU2019360210A1 (en) * | 2018-10-17 | 2021-06-10 | Xibin Liao | 6-Mercaptopurine nucleoside analogues |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57209226A (en) | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
EP0570519B1 (en) | 1991-02-08 | 1999-05-06 | Pro-Neuron, Inc. | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis |
EP1879657A2 (en) | 2005-04-25 | 2008-01-23 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Use of compounds to enhance processivity of telomerase |
CN101220071B (zh) * | 2008-01-17 | 2011-04-06 | 南京长澳医药科技有限公司 | 稳定的6-甲氧基-2’,3’-双脱氧鸟嘌呤核苷及其制备方法和包含它的药物组合物 |
US20100323979A1 (en) | 2009-06-16 | 2010-12-23 | Weis-Amon Angelika B | Methods and compositions for inhibiting proliferation of aneuploid cells |
-
2014
- 2014-04-08 SG SG11201508336TA patent/SG11201508336TA/en unknown
- 2014-04-08 RU RU2015147555A patent/RU2713555C2/ru active
- 2014-04-08 AU AU2014251093A patent/AU2014251093B2/en not_active Ceased
- 2014-04-08 JP JP2016507608A patent/JP6525956B2/ja active Active
- 2014-04-08 BR BR112015025206A patent/BR112015025206A2/pt not_active Application Discontinuation
- 2014-04-08 MX MX2015014159A patent/MX2015014159A/es unknown
- 2014-04-08 CN CN201480032692.6A patent/CN105338987A/zh active Pending
- 2014-04-08 KR KR1020157031880A patent/KR20150143587A/ko not_active Application Discontinuation
- 2014-04-08 CN CN201910445731.XA patent/CN110339203A/zh active Pending
- 2014-04-08 SG SG10202002556QA patent/SG10202002556QA/en unknown
- 2014-04-08 WO PCT/US2014/033330 patent/WO2014168947A2/en active Application Filing
- 2014-04-08 CA CA2907924A patent/CA2907924C/en active Active
- 2014-04-08 NZ NZ713498A patent/NZ713498A/en not_active IP Right Cessation
- 2014-04-08 US US14/247,967 patent/US10463685B2/en active Active
- 2014-04-08 EP EP20155920.0A patent/EP3682888A1/en active Pending
- 2014-04-08 EP EP14726468.3A patent/EP2983675A2/en not_active Withdrawn
-
2016
- 2016-06-27 HK HK16107437.8A patent/HK1219418A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3682888A1 (en) | 2020-07-22 |
US10463685B2 (en) | 2019-11-05 |
EP2983675A2 (en) | 2016-02-17 |
RU2713555C2 (ru) | 2020-02-05 |
CN105338987A (zh) | 2016-02-17 |
JP2016516773A (ja) | 2016-06-09 |
AU2014251093B2 (en) | 2017-06-15 |
NZ732228A (en) | 2020-11-27 |
NZ713498A (en) | 2017-07-28 |
RU2015147555A (ru) | 2017-05-15 |
JP6525956B2 (ja) | 2019-06-05 |
SG11201508336TA (en) | 2015-11-27 |
WO2014168947A3 (en) | 2015-02-19 |
US20140303239A1 (en) | 2014-10-09 |
CA2907924A1 (en) | 2014-10-16 |
MX2015014159A (es) | 2016-06-21 |
SG10202002556QA (en) | 2020-04-29 |
AU2014251093A1 (en) | 2015-10-15 |
WO2014168947A9 (en) | 2014-12-31 |
CN110339203A (zh) | 2019-10-18 |
HK1219418A1 (zh) | 2017-04-07 |
KR20150143587A (ko) | 2015-12-23 |
WO2014168947A2 (en) | 2014-10-16 |
CA2907924C (en) | 2022-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015009624A2 (pt) | inibidores de tirosina cinase de bruton | |
DOP2016000071A (es) | Inhibidores de tirosina cinasa de bruton | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
BR112015029386A8 (pt) | uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit | |
BR112015011171A2 (pt) | compostos de pirrolopirimidina como inibidores da quinase | |
BR112015008447A2 (pt) | métodos para tratar câncer | |
EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
BR112015024678A2 (pt) | inibidor da cinase | |
BR112015021888A2 (pt) | inibidores de dna-ik | |
MX2015005963A (es) | Inhibidores heterociclicos de glutaminasa. | |
DOP2013000239A (es) | Derivados de ácido 3-fenilpropiónico ramificados y su uso. | |
BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
BR112015022514A2 (pt) | composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial | |
BR112015028278A2 (pt) | processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos | |
MY171831A (en) | Novel fused pyrimidine compound or salt thereof | |
BR112015029463A2 (pt) | bissulfato do inibidor da janus quinase (jak) e método de preparação do mesmo | |
BR112014006587A8 (pt) | Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes | |
BR112013029999A2 (pt) | derivados de tiazol | |
BR112015018504A2 (pt) | moduladores de flap | |
BR112015025206A2 (pt) | compostos alterando telômero mediados por telomerase | |
CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso | |
BR112016029012A2 (pt) | método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina | |
MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
MX2016005900A (es) | Profarmaco mutuo que comprende acidos grasos de cadena corta y zebularina o 1'-ciano-citarabina para tratamiento del cancer. | |
BR112014016804A2 (pt) | composições, métodos de uso e métodos de tratamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |